ReviewClinical interventions in aging2023
Clinical and Therapeutic Considerations for Older Adults with Head and Neck Cancer.
Review in Clinical interventions in aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Time-dependent analysis of HUS change in older patients aged > 75 years with head and neck cancer.Health and quality of life outcomes · 2026Article
- Health adjusted age and surgical outcomes in elderly oral cavity cancer patients: a case series from the Indian subcontinent.Oral and maxillofacial surgery · 2026Article
- Dexmedetomidine for Conscious Sedation and Controlled Hypotension in Head and Neck Surgery: A Single-Centre Experience.Medicina (Kaunas, Lithuania) · 2026Observational
- Article
- Pushing the boundaries - perioperative risk assessment and short-term surgical outcomes in octogenarian patients with head and neck cancer: comparison with non-oncological elderlies.Frontiers in oncology · 2026Article
- Trends and Drivers of Head and Neck Cancers in Older Adults Over 30 Years: A Population-Based Modelling Study.Risk management and healthcare policy · 2026Article
- Skeletal Muscle Radiation Attenuation at C3 Predicts Survival in Head and Neck Cancer.Current oncology (Toronto, Ont.) · 2025Article
- Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.Frontiers in oncology · 2025Article
- The status quo of global geriatric radiation oncology education: A scoping review.Technical innovations & patient support in radiation oncology · 2024Article
- Frailty and Overall Survival of Older Patients Undergoing Radiotherapy for Head and Neck Cancer: A Prospective Analysis.Cancers · 2024Article
- Efficacy of chemoradiotherapy in elderly patients with stage IV inoperable head and neck cancer.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- Transoral Laser Microsurgery and Transoral Robotic Surgery in Aging Patients: A State-of-The-Art Review.Clinical interventions in aging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 30% of patients with head and neck squamous cell carcinoma (HNSCC) are at least 70 years of age, and this percentage is expected to increase as the population increases and lives longer. Elderly patients are underrepresented in head and neck oncology clinical trials, and there is minimal evidence on the management of HNSCC for this population. Subsequently, despite their best intentions, physicians may unknowingly recommend an ill-suited course of therapy, which may result in suboptimal oncological or functional outcomes or adverse events. Surgical approaches have the potential to carry a higher risk of morbidity and mortality in older adults, especially in patients with multiple comorbidities. Definitive radiation therapy treatment in patients with HNSCC frequently involves 7 weeks of daily radiation, sometimes with concurrent chemotherapy, and this demanding treatment can be difficult for older adult patients, which may lead to treatment interruptions, potential removal of concurrent systemic therapy, compromised outcomes, and diminished quality of life. There are clinical trials currently underway investigating altered fractionation regimens and novel, less toxic systemic treatments in this population. This review provides an overview of how best to approach an older adult with HNSCC, from initial work-up to treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.